共 50 条
Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
被引:0
|作者:
de Weerdt, Iris
[1
,2
]
Kater, Arnon P.
[1
,2
]
机构:
[1] Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam Infect & Immun Inst, Dept Hematol,Amsterdam UMC, Amsterdam, Netherlands
[2] LYMMCARE, Lymphoma & Myeloma Ctr Amsterdam, Amsterdam, Netherlands
来源:
关键词:
OBINUTUZUMAB;
VENETOCLAX;
D O I:
10.1097/HS9.0000000000000197
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Take home messages Although the novel agents ibrutinib and venetoclax are effective in chronic lymphocytic leukemia, their use as monotherapeutic agents requires continuous treatment. Combination strategies with novel agents can induce deep remissions and durable disease control following treatment cessation. Future studies will evaluate possibilities to tailor treatment duration to individual responses.
引用
收藏
页码:44 / 46
页数:3
相关论文